Last checked at 19 Oct 2020 07:00
This is an RNS Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.
IXICO plc
("IXICO" or the "Company")
IXICO to Present at SCA & ARCA Global Conference
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that Dr Robin Wolz, Senior Vice President of Science & Innovation at IXICO, will present on the industry panel at the virtual SCA & ARCA Global Conference, taking place on 19-21 October 2020.
The SCA & ARCA Global Conference brings together two initiatives that focus on ataxia, which is the loss of coordination of voluntary muscle movements. This platform allows for academic and industry leaders, physicians and companies working in the space to collaborate on developing future treatments for patients.
Autosomal-recessive cerebellar ataxias (ARCA) are a heterogeneous group of rare degenerative and metabolic genetic diseases recessively inherited and spinocerebellar ataxias (SCAs) are a group of autosomal dominantly inherited progressive ataxia disorders. The clinical manifestations of hereditary ataxias are poor coordination of movement and unsteady gait.
Dr Robin Wolz will be presenting on the industry panel on 20 October at 16.20 (BST). The talk is titled: "Challenges and opportunities in the deployment of volumetric MRI in SCA clinical trials." Additionally, IXICO are supporting the conference as an official partner of SCA & ARCA Global 2020.
Dr Robin Wolz, Senior Vice President, Science & Innovation at IXICO commented: "Ataxia conditions continue to be a focus for IXICO in its efforts to provide pioneering technologies to support the advancement of effective treatments for rare neurological diseases. Our research in imaging analytics will provide an insight into the best methods for monitoring both the progression of the disease as well as the potential effect of interventional treatments."
Additional info can be found on the conference website: http://ataxia-global-initiatives.net/sca-global/conferences/sca-global-2020/
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
|
| |||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales) |
| |||
|
| |||
Walbrook PR Ltd | Tel: +44 (0) 20 7933 8780 or IXICO@walbrookpr.com | |||
Paul McManus / Lianne Cawthorne / Alice Woodings |
| |||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc